Description

XTANE 25 MG TAB (1X30)

Indications

XTANE 25 MG TAB is primarily indicated for the treatment of certain types of breast cancer in postmenopausal women. It is specifically used in patients with hormone receptor-positive tumors. The medication is often prescribed as part of a comprehensive treatment plan that may include surgery, radiation therapy, and other medications. XTANE may also be utilized in the adjuvant setting to reduce the risk of cancer recurrence following surgery.

Mechanism of Action

XTANE, containing the active ingredient anastrozole, is classified as an aromatase inhibitor. Its mechanism of action involves the inhibition of the aromatase enzyme, which is responsible for converting androgens into estrogens in peripheral tissues. By reducing estrogen levels in the body, XTANE effectively deprives estrogen-sensitive tumors of the hormone necessary for their growth. This reduction in estrogen can lead to a decrease in tumor size and a slowdown in the progression of breast cancer.

Pharmacological Properties

XTANE exhibits a high affinity for the aromatase enzyme, resulting in potent inhibition of estrogen synthesis. The pharmacokinetics of anastrozole indicate that it is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 2 hours. The drug has a half-life of approximately 50 hours, allowing for once-daily dosing. XTANE is primarily metabolized in the liver, and its metabolites are excreted via the urine. The pharmacological profile of XTANE supports its effectiveness in lowering estrogen levels, which is crucial for managing hormone receptor-positive breast cancer.

Contraindications

XTANE is contraindicated in patients with known hypersensitivity to anastrozole or any of its components. Additionally, it should not be used in premenopausal women, as the drug is designed specifically for postmenopausal patients. The use of XTANE is also contraindicated during pregnancy and breastfeeding due to potential harm to the fetus or nursing infant. Patients with severe liver impairment should use this medication with caution, as it may exacerbate their condition.

Side Effects

Common side effects associated with the use of XTANE include hot flashes, joint pain, fatigue, and nausea. Some patients may experience headaches, mood changes, or gastrointestinal disturbances. More serious side effects can include bone density loss, which may increase the risk of fractures, and cardiovascular issues such as hypertension. It is essential for patients to report any severe or persistent side effects to their healthcare provider for appropriate management.

Dosage and Administration

The recommended dosage of XTANE is one 25 mg tablet taken orally once daily. It is advised to take the medication at the same time each day to maintain consistent blood levels. Patients should continue treatment for as long as prescribed by their healthcare provider, typically for a duration of five years in the adjuvant setting. It is important not to exceed the recommended dose, and patients should not discontinue use without consulting their physician.

Interactions

XTANE may interact with other medications, which can affect its efficacy or increase the risk of adverse effects. Notably, the use of estrogen-containing therapies can counteract the effects of XTANE and should be avoided. Additionally, drugs that are strong inducers or inhibitors of cytochrome P450 2A6 may alter the metabolism of anastrozole. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Before initiating treatment with XTANE, healthcare providers should assess patients for any pre-existing conditions, particularly those related to liver function and bone health. Regular monitoring of bone density is recommended, especially in patients at risk for osteoporosis. Patients should also be advised to maintain a healthy lifestyle, including a balanced diet and regular exercise, to support overall health during treatment. Women of childbearing age should be counseled on effective contraception methods while taking XTANE.

Clinical Studies

Clinical studies have demonstrated the efficacy of XTANE in reducing the risk of breast cancer recurrence in postmenopausal women with hormone receptor-positive tumors. In pivotal trials, patients treated with anastrozole showed improved disease-free survival rates compared to those receiving tamoxifen. Furthermore, studies have indicated that anastrozole has a favorable side effect profile compared to other hormonal therapies, making it a preferred choice for many clinicians in managing postmenopausal breast cancer.

Conclusion

XTANE 25 MG TAB is a critical component in the management of hormone receptor-positive breast cancer in postmenopausal women. Its mechanism of action as an aromatase inhibitor effectively lowers estrogen levels, which is vital for controlling tumor growth. While generally well-tolerated, patients should be aware of potential side effects and interactions with other medications. Ongoing clinical studies continue to support the efficacy and safety of XTANE, reinforcing its role in breast cancer treatment protocols.